gocer proposed galectin 3 concentration ranges (Galectin Therapeutics)
86
Structured Review
Galectin Therapeutics
gocer proposed galectin 3 concentration ranges
Gocer Proposed Galectin 3 Concentration Ranges, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/concentration+range/pmc12504382-74-0-2
Average 86 stars, based on 1 article reviews
Gocer Proposed Galectin 3 Concentration Ranges, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/concentration+range/pmc12504382-74-0-2
Average 86 stars, based on 1 article reviews
gocer proposed galectin 3 concentration ranges - by Bioz Stars,
2026-11
86/100 stars
Images
Related Articles
other:Article Title: The Emerging Role of Galectins and O -GlcNAc Homeostasis in Processes of Cellular Differentiation Article Snippet: Article Title: Low or No Inhibitory Potency of the Canonical Galectin Carbohydrate-binding Site by Pectins and Galactomannans Article Snippet: Additionally, a low molecular mass high affinity galectin-3 antagonist, 33DFTG (with K d value in the low nanomolar range, also known as TD139) , was tested in both hemagglutination assays and was shown to have Article Title: Methodology and Technical Requirements of the Galectin-3 Test for the Preoperative Characterization of Thyroid Nodules Article Snippet: In the last decade, the b-galactosyl binding protein galectin-3 has been the object of extensive molecular, structural, and functional studies aimed to clarify its biological role in cancer.. Multicenter studies also contributed to discover the potential clinical value of galectin-3 expression analysis in distinguishing, preoperatively, benign from malignant thyroid nodules.. As a consequence galectin-3 is receiving significant attention as tumor marker for thyroid cancer diagnosis, but some conflicting results mostly owing to methodological problems have been published. Article Title: Galectin-1-Binding Glycoforms of Haptoglobin with Altered Intracellular Trafficking, and Increase in Metastatic Breast Cancer Patients Article Snippet: This was due to the binding of a larger fraction of Concentration Assay:Article Title: HMGB1-Induced Neurite Outgrowth in the Dorsal Root Ganglion Neurons and Regeneration Priming after their Axonal Injury by Sciatic Nerve Crush. Article Snippet: 1 Laboratory of Pharmacology and Pathophysiology, Faculty of Pharmacy, Kindai University, 3-4-1 Kowakae, Higashi 577-8502, Osaka, Japan 2 Department of Translational Research and Drug Development, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata-cho, Okayama 700-8558, Japan Abstract High mobility group box 1 (HMGB1), a nuclear protein, once released extracellularly, exists in two different active forms, i.e., all-thiol (at)and disulfide (ds)-HMGB1.. Given that HMGB1 promotes neuritogenesis, we examined whether at/ ds-HMGB1 would promote neuritogenesis in dorsal root ganglion (DRG) neurons, and participate in regeneration priming of DRG neurons by sciatic nerve crush (SNC).. In cultured mouse DRG neurons, at-HMGB1, but not ds-HMGB1, accelerated neuritogenesis, an effect blocked by an antagonist of receptor for advanced glycation end-product (RAGE). |